Artiva Biotherapeutics (NASDAQ:ARTV) Insider Sells $63,088.02 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Christopher Horan sold 7,002 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total transaction of $63,088.02. Following the transaction, the insider directly owned 293,450 shares of the company’s stock, valued at $2,643,984.50. This represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Up 1.9%

Artiva Biotherapeutics stock opened at $7.99 on Friday. Artiva Biotherapeutics, Inc. has a twelve month low of $1.47 and a twelve month high of $14.53. The firm has a 50 day moving average price of $8.40 and a 200-day moving average price of $5.70. The company has a market capitalization of $197.51 million, a P/E ratio of -2.26 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics in the 3rd quarter worth approximately $41,000. Bank of America Corp DE boosted its holdings in Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the period. Dimensional Fund Advisors LP bought a new position in Artiva Biotherapeutics in the 1st quarter valued at $131,000. OMERS ADMINISTRATION Corp bought a new position in Artiva Biotherapeutics in the 4th quarter valued at $91,000. Finally, Sanctuary Advisors LLC bought a new position in Artiva Biotherapeutics in the 1st quarter valued at $139,000.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Cantor Fitzgerald increased their target price on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Needham & Company LLC increased their target price on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.